Sunshine Biopharma, Inc. (SBFM) NASDAQ
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Currency In USD
Address
6500 Trans-Canada Highway
Pointe-Claire, QC H9R 0A5
Canada
Phone
514 426 6161
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
52
First IPO Date
February 15, 2022
| Name | Title | Pay | Year Born |
| Steve N. Slilaty | Chairman, President & Chief Executive Officer | 545,953 | 1952 |
| Michel Roy | Chief Commercial Officer | 283,166 | 1968 |
| Camille Sebaaly | CFO, Secretary & Director | 412,278 | 1959 |
| Robert G. Ferreira | President of Sunshine Bio Investments Inc | 0 | 1962 |
| Malek Chamoun | Chief Development Officer | 0 | 1985 |
Sunshine Biopharma, Inc. operates as a pharmaceutical entity and a provider of nutritional supplements, primarily dedicating its efforts to the research and development of novel anticancer therapies. A key pipeline candidate is Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin, designed to combat a broad spectrum of malignancies, including leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, and liver cancers. Notably, Adva-27a also demonstrates efficacy against multidrug-resistant cancer cells, encompassing pancreatic, breast, small-cell lung, and uterine sarcoma cells. The company is also progressing SBFM-PL4, a compound under development as an anti-coronavirus treatment. In addition to its drug development, Sunshine Biopharma markets a range of nutritional products, such as the Essential 9 tablet and the Essential Calcium-Vitamin D supplement, alongside other scientifically formulated dietary aids. A collaboration with the University of Georgia supports the ongoing advancement of SBFM-PL4 as an anti-coronavirus agent. The firm's headquarters are situated in Pointe-Claire, Canada.